Pharmacological management of invasive mold infections in solid organ transplant recipients

References

• Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis. 2005;41(1):52–59. doi: 10.1086/430602
   PubMed Web of Science ®Google Scholar
• Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the transplant-associated infection surveillance network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–1111. doi: 10.1086/651262
   PubMed Web of Science ®Google Scholar
• Neofytos D, Chatzis O, Nasioudis D, et al. Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss transplant cohort study. Transpl Infect Dis. 2018;20(4):e12898. doi: 10.1111/tid.12898
   PubMed Web of Science ®Google Scholar
• Gavaldà J, Meije Y, Fortún J, et al. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014;20(Suppl 7):27–48. doi: 10.1111/1469-0691.12660
   PubMed Web of Science ®Google Scholar
• López-Medrano F, Fernández-Ruiz M, Silva JT, et al. Clinical presentation and determinants of mortality of invasive pulmonary aspergillosis in kidney transplant recipients: a multinational cohort study. Am J Transplant. 2016;16(11):3220–3234. doi: 10.1111/ajt.13837
   PubMed Web of Science ®Google Scholar
• Saliba F, Pascher A, Cointault O, et al. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients. Clin Infect Dis. 2015;60(7):997–1006. doi: 10.1093/cid/ciu1128
   PubMed Web of Science ®Google Scholar
• Fortun J, Martin-Davila P, Montejo M, et al. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients. Transplantation. 2009;87(3):424–435. doi: 10.1097/TP.0b013e3181932e76
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M, Cardozo C, Salavert M, et al. Candidemia in solid organ transplant recipients in Spain: epidemiological trends and determinants of outcome. Transpl Infect Dis. 2019;21(6):e13195. doi: 10.1111/tid.13195
   PubMed Web of Science ®Google Scholar
• O’Halloran JA, Powderly WG, Spec A. Cryptococcosis today: it is not all about HIV infection. Curr Clin Microbiol Rep. 2017;4(2):88–95. doi: 10.1007/s40588-017-0064-8
   PubMed Web of Science ®Google Scholar
• Trujillo H, Fernández-Ruiz M, Gutierrez E, et al. Invasive pulmonary aspergillosis associated with COVID-19 in a kidney transplant recipient. Transpl Infect Dis. 2021;23(2):e13501. doi: 10.1111/tid.13501
   PubMed Web of Science ®Google Scholar
• Donnelly JP, De Pauw BE. Voriconazole-a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect. 2004;10(Suppl 1):107–117. doi: 10.1111/j.1470-9465.2004.00838.x
   PubMed Web of Science ®Google Scholar
• Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther. 2004;2(4):485–497. doi: 10.1586/14787210.2.4.485
   PubMedGoogle Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–415. doi: 10.1056/NEJMoa020191
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–571. doi: 10.1086/324620
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122–1131. doi: 10.1086/374557
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46(3):327–360. doi: 10.1086/525258
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Zafiropoulou R, Giotakis J, et al. Deep sinus aspergillosis in a liver transplant recipient successfully treated with a combination of caspofungin and voriconazole. Transpl Infect Dis. 2004;6(1):37–40. doi: 10.1111/j.1399-3062.2004.00039.x
   PubMedGoogle Scholar
• Levin T, Suh B, Beltramo D, et al. Aspergillus mediastinitis following orthotopic heart transplantation: case report and review of the literature. Transpl Infect Dis. 2004;6(3):129–131. doi: 10.1111/j.1399-3062.2004.00064.x
   PubMedGoogle Scholar
• Fortun J, Martin-Davila P, Sanchez MA, et al. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis. 2003;22(7):408–413. doi: 10.1007/s10096-003-0960-0
   PubMed Web of Science ®Google Scholar
• Baden LR, Katz JT, Fishman JA, et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation. 2003;76(11):1632–1637. doi: 10.1097/01.TP.0000089109.42239.75
   PubMed Web of Science ®Google Scholar
• Wieland T, Liebold A, Jagiello M, et al. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation. J Heart Lung Transplant. 2005;24(1):102–104. doi: 10.1016/j.healun.2003.10.014
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24:e1–e38. doi: 10.1016/j.cmi.2018.01.002
   PubMed Web of Science ®Google Scholar
• Husain S, Camargo JF. Invasive aspergillosis in solid-organ transplant recipients: guidelines from the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13544.
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Mazzocato S, Mazzanti S, et al. Invasive aspergillosis in liver transplant recipients: epidemiology, clinical characteristics, treatment, and outcomes in 116 cases. Liver Transpl. 2015;21(2):204–212. doi: 10.1002/lt.24032
   PubMed Web of Science ®Google Scholar
• Farges C, Cointault O, Murris M, et al. Outcomes of solid organ transplant recipients with invasive aspergillosis and other mold infections. Transpl Infect Dis. 2020;22(1):e13200. doi: 10.1111/tid.13200
   PubMed Web of Science ®Google Scholar
• Veroux M, Corona D, Gagliano M, et al. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc. 2007;39(6):1838–1840. doi: 10.1016/j.transproceed.2007.05.012
   PubMed Web of Science ®Google Scholar
• Abe K, Shinoda M, Uno S, et al. Invasive pulmonary aspergillosis after liver transplantation: lessons from successfully treated cases and review of the literature. Surg Today. 2021;51(8):1361–1370. doi: 10.1007/s00595-021-02263-z
   PubMed Web of Science ®Google Scholar
• Neofytos D, Treadway S, Ostrander D, et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis. 2013;15(3):233–242. doi: 10.1111/tid.12060
   PubMed Web of Science ®Google Scholar
• Baddley JW, Andes DR, Marr KA, et al. Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol. 2013;51(2):128–135. doi: 10.3109/13693786.2012.690108
   PubMed Web of Science ®Google Scholar
• Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis. 2003;37(5):728–732. doi: 10.1086/377131
   PubMed Web of Science ®Google Scholar
• Weiler S, Fiegl D, MacFarland R, et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother. 2011;55(2):925–928. doi: 10.1128/AAC.00949-10
   PubMed Web of Science ®Google Scholar
• Schwartz S, Reisman A, Troke PF. The efficacy of voriconazole in the treatment of 192 fungal central nervous system infections: a retrospective analysis. Infection. 2011;39(3):201–210. doi: 10.1007/s15010-011-0108-6
   PubMed Web of Science ®Google Scholar
• Kramer M, Kramer MR, Blau H, et al. Intravitreal voriconazole for the treatment of endogenous aspergillus endophthalmitis. Ophthalmol. 2006;113(7):1184–1186. doi: 10.1016/j.ophtha.2006.01.059
   PubMed Web of Science ®Google Scholar
• Ferreira TB, Vaz F, Rodrigues A, et al. Intravitreal voriconazole as primary treatment for endogenous Aspergillus endophthalmitis. BMJ Case Rep. 2009;2009(may21 1):bcr1020081110. doi: 10.1136/bcr.10.2008.1110
   PubMedGoogle Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi: 10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Lewis RE. The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy. Expert Opin Investig Drugs. 2003;12(8):1313–1333. doi: 10.1517/13543784.12.8.1313
   PubMed Web of Science ®Google Scholar
• Raasch RH. Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther. 2004;2(4):499–508. doi: 10.1586/14787210.2.4.499
   PubMedGoogle Scholar
• Hiemenz JW, Raad II, Maertens JA, et al. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort. Eur J Clin Microbiol Infect Dis. 2010;29(11):1387–1394. doi: 10.1007/s10096-010-1013-0
   PubMed Web of Science ®Google Scholar
• Aguado JM, Varo E, Usetti P, et al. Safety of anidulafungin in solid organ transplant recipients. Liver Transpl. 2012;18(6):680–685. doi: 10.1002/lt.23410
   PubMed Web of Science ®Google Scholar
• Winkler M, Pratschke J, Schulz U, et al. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study. Transpl Infect Dis. 2010;12(3):230–237. doi: 10.1111/j.1399-3062.2009.00490.x
   PubMed Web of Science ®Google Scholar
• Petrovic J, Ngai A, Bradshaw S, et al. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc. 2007;39(10):3117–3120. doi: 10.1016/j.transproceed.2007.10.003
   PubMed Web of Science ®Google Scholar
• Groetzner J, Kaczmarek I, Wittwer T, et al. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant. 2008;27(1):1–6. doi: 10.1016/j.healun.2007.10.002
   PubMed Web of Science ®Google Scholar
• Keating G, Figgitt D. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs. 2003;63(20):2235–2263. doi: 10.2165/00003495-200363200-00008
   PubMed Web of Science ®Google Scholar
• Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother. 2015;49(7):825–842. doi: 10.1177/1060028015581679
   PubMed Web of Science ®Google Scholar
• Owusu Obeng A, Egelund EF, Alsultan A, et al. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? Pharmacotherapy. 2014;34(7):703–718. doi: 10.1002/phar.1400
   PubMed Web of Science ®Google Scholar
• Wu X, Clancy CJ, Rivosecchi RM, et al. Pharmacokinetics of intravenous isavuconazole in solid-organ transplant recipients. Antimicrob Agents Chemother. 2018;62(12). doi: 10.1128/AAC.01643-18
   Web of Science ®Google Scholar
• Kim SH, Kwon JC, Park C, et al. Therapeutic drug monitoring and safety of intravenous voriconazole formulated with sulfobutylether beta-cyclodextrin in haematological patients with renal impairment. Mycoses. 2016;59(10):644–651. doi: 10.1111/myc.12517
   PubMed Web of Science ®Google Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769. doi: 10.1016/S0140-6736(15)01159-9
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz M, Bodro M, Gutierrez Martin I, et al. Isavuconazole for the treatment of invasive mold disease in solid organ transplant recipients: a multicenter study on efficacy and safety in real-life clinical practice. Transplantation. 2023;107(3):762–773. doi: 10.1097/TP.0000000000004312
   PubMed Web of Science ®Google Scholar
• Monforte A, Los-Arcos I, Martin-Gomez MT, et al. Safety and effectiveness of isavuconazole treatment for fungal infections in solid organ transplant recipients (ISASOT study). Microbiol Spectr. 2022;10(1):e0178421. doi: 10.1128/spectrum.01784-21
   PubMed Web of Science ®Google Scholar
• Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499–509. doi: 10.1016/S0140-6736(21)00219-1
   PubMed Web of Science ®Google Scholar
• Kersemaekers WM, Dogterom P, Xu J, et al. Effect of a high‐fat meal on the pharmacokinetics of 300‐milligram posaconazole in a solid oral tablet formulation. Antimicrob Agents Chemother. 2015;59(6):3385–3389. doi: 10.1128/AAC.05000-14
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther. 2009;31(2):286–298. doi: 10.1016/j.clinthera.2009.02.022
   PubMed Web of Science ®Google Scholar
• Gu TM, Lewis JS, Le H, et al. Comparative effects of fluconazole, posaconazole, and isavuconazole upon tacrolimus and cyclosporine serum concentrations. J Oncol Pharm Pract. 2022;28(6):1357–1362. doi: 10.1177/10781552211029046
   PubMed Web of Science ®Google Scholar
• Chanoine S, Gautier-Veyret E, Pluchart H, et al. Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus. Br J Clin Pharmacol. 2021;87(2):427–435. doi: 10.1111/bcp.14398
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405–e421. doi: 10.1016/S1473-3099(19)30312-3
   PubMed Web of Science ®Google Scholar
• Linden P, Williams P, Chan KM. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections. Clin Transplant. 2000;14(4 Pt 1):329–339. doi: 10.1034/j.1399-0012.2000.140409.x
   PubMed Web of Science ®Google Scholar
• Forrest GN, Mankes K. Outcomes of invasive zygomycosis infections in renal transplant recipients. Transpl Infect Dis. 2007;9(2):161–164. doi: 10.1111/j.1399-3062.2006.00197.x
   PubMed Web of Science ®Google Scholar
• Sun HY, Forrest G, Gupta KL, et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation. 2010;90(1):85–92. doi: 10.1097/TP.0b013e3181dde8fc
   PubMed Web of Science ®Google Scholar
• Sun HY, Aguado JM, Bonatti H, et al. Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant. 2009;9(9):2166–2171. doi: 10.1111/j.1600-6143.2009.02754.x
   PubMed Web of Science ®Google Scholar
• Husain S, Alexander BD, Munoz P, et al. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin Infect Dis. 2003;37(2):221–229. doi: 10.1086/375822
   PubMed Web of Science ®Google Scholar
• Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis. 2011;17(10):1855–1864. doi: 10.3201/eid1710.110087
   PubMed Web of Science ®Google Scholar
• Song Y, Qiao J, Giovanni G, et al. Mucormycosis in renal transplant recipients: review of 174 reported cases. BMC Infect Dis. 2017;17(1):283. doi: 10.1186/s12879-017-2381-1
   PubMed Web of Science ®Google Scholar
• Coste A, Conrad A, Porcher R, et al. Improving diagnosis of pulmonary mucormycosis: leads from a contemporary national study of 114 cases. Chest. 2023;164(5):S0012–3692(23)00946–7. doi: 10.1016/j.chest.2023.06.039
   Web of Science ®Google Scholar
• Bansal SB, Rana A, Babras M, et al. Risk factors and outcomes of COVID associated mucormycosis in kidney transplant recipients. Transpl Infect Dis. 2022;24(2):e13777. doi: 10.1111/tid.13777
   PubMed Web of Science ®Google Scholar
• Meshram HS, Kute VB, Chauhan S, et al. Mucormycosis in post-COVID-19 renal transplant patients: a lethal complication in follow-up. Transpl Infect Dis. 2021;23(4):e13663. doi: 10.1111/tid.13663
   PubMed Web of Science ®Google Scholar
• Tobon AM, Arango M, Fernandez D, et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. Clin Infect Dis. 2003;36(11):1488–1491. doi: 10.1086/375075
   PubMed Web of Science ®Google Scholar
• Deyo JC, Nicolsen N, Lachiewicz A, et al. Salvage treatment of mucormycosis post-liver transplant with posaconazole during sirolimus maintenance immunosuppression. J Pharm Pract. 2017;30(2):261–265. doi: 10.1177/0897190016628702
   PubMedGoogle Scholar
• Gani I, Doroodchi A, Falkenstrom K, et al. Gastric mucormycosis in a renal transplant patient treated with isavuconazole monotherapy. Case Rep Transplant. 2019;2019:9839780. doi: 10.1155/2019/9839780
   PubMedGoogle Scholar
• Hoellinger B, Magnus L, Ruch Y, et al. Case report and literature review of prosthetic cardiovascular mucormycosis. Emerg Infect Dis. 2023;29(11):2388–2390. doi: 10.3201/eid2911.230837
   PubMed Web of Science ®Google Scholar
• Klimova K, Padilla Suarez C, Pelaez T, et al. Cutaneous mucormycosis as a rare complication of a liver transplantation. Enferm Infec Microbiol Clin. 2014;32(8):537–539. in Spanish. doi: 10.1016/j.eimc.2014.05.007
   PubMed Web of Science ®Google Scholar
• Abboud CS, Bergamasco MD, Baia CE, et al. Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy. Transplant Proc. 2012;44(8):2501–2502. doi: 10.1016/j.transproceed.2012.07.042
   PubMed Web of Science ®Google Scholar
• Martin MS, Smith AA, Lobo M, et al. Successful treatment of recurrent pulmonary mucormycosis in a renal transplant patient: a case report and literature review. Case Rep Transplant. 2017;2017:1925070. doi: 10.1155/2017/1925070
   PubMedGoogle Scholar
• Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126–133. doi: 10.1128/AAC.50.1.126-133.2006
   PubMed Web of Science ®Google Scholar
• Wand O, Unterman A, Izhakian S, et al. Mucormycosis in lung transplant recipients: a systematic review of the literature and a case series. Clin Transplant. 2020;34(2):e13774. doi: 10.1111/ctr.13774
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837. doi: 10.1016/S1473-3099(16)00071-2
   PubMed Web of Science ®Google Scholar
• Panackal AA. Combination antifungal therapy for invasive aspergillosis revisited. Med Mycol Open Access. 2016;2(2). doi: 10.21767/2471-8521.100012
   PubMedGoogle Scholar
• Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89. doi: 10.7326/M13-2508
   PubMed Web of Science ®Google Scholar
• Raad II, Zakhem AE, Helou GE, et al. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45(3):283–288. doi: 10.1016/j.ijantimicag.2014.08.012
   PubMed Web of Science ®Google Scholar
• Wattier RL, Dvorak CC, Hoffman JA, et al. A prospective, international cohort study of invasive mold infections in children. J Pediatric Infect Dis Soc. 2015;4(4):313–322. doi: 10.1093/jpids/piu074
   PubMed Web of Science ®Google Scholar
• Munoz P, Singh N, Bouza E. Treatment of solid organ transplant patients with invasive fungal infections: should a combination of antifungal drugs be used? Curr Opin Infect Dis. 2006;19(4):365–370.
   PubMed Web of Science ®Google Scholar
• Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81(3):320–326. doi: 10.1097/01.tp.0000202421.94822.f7
   PubMed Web of Science ®Google Scholar
• Spellberg B, Fu Y, Edwards JE Jr., et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother. 2005;49(2):830–832. doi: 10.1128/AAC.49.2.830-832.2005
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556–1558. doi: 10.1128/AAC.01458-07
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–371. doi: 10.1086/589857
   PubMed Web of Science ®Google Scholar
• Abidi MZ, Sohail MR, Cummins N, et al. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies. Mycoses. 2014;57(11):687–698. doi: 10.1111/myc.12222
   PubMed Web of Science ®Google Scholar
• Rodriguez MM, Serena C, Marine M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by rhizopus oryzae. Antimicrob Agents Chemother. 2008;52(10):3786–3788. doi: 10.1128/AAC.00628-08
   PubMed Web of Science ®Google Scholar
• Gebremariam T, Gu Y, Singh S, et al. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. J Antimicrob Chemother. 2021;76(10):2636–2639. doi: 10.1093/jac/dkab233
   PubMed Web of Science ®Google Scholar
• Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. Emerg Infect Dis. 2021;27(9):2349–2359. doi: 10.3201/eid2709.210934
   PubMed Web of Science ®Google Scholar
• Groll AH, Townsend R, Desai A, et al. Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4. Transpl Infect Dis. 2017;19(5). doi: 10.1111/tid.12751
   PubMed Web of Science ®Google Scholar
• Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cyclosporin a and FK506. J Biol Chem. 1993;268(9):6077–6080. doi: 10.1016/S0021-9258(18)53221-X
   PubMed Web of Science ®Google Scholar
• Marfo K, Altshuler J, Lu A. Tacrolimus pharmacokinetic and pharmacogenomic differences between adults and pediatric solid organ transplant recipients. Pharmaceutics. 2010;2(3):291–299. doi: 10.3390/pharmaceutics2030291
   PubMedGoogle Scholar
• Hesselink DA, Bouamar R, Elens L, et al. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2014;53(2):123–139. doi: 10.1007/s40262-013-0120-3
   PubMed Web of Science ®Google Scholar
• Brunet M, van Gelder T, Asberg A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261–307. doi: 10.1097/FTD.0000000000000640
   PubMed Web of Science ®Google Scholar
• Rivosecchi RM, Samanta P, Demehin M, et al. Pharmacokinetics of azole antifungals in cystic fibrosis. Mycopathologia. 2018;183(1):139–150. doi: 10.1007/s11046-017-0189-6
   PubMed Web of Science ®Google Scholar
• Schulz J, Kluwe F, Mikus G, et al. Novel insights into the complex pharmacokinetics of voriconazole: a review of its metabolism. Drug Metab Rev. 2019;51(3):247–265. doi: 10.1080/03602532.2019.1632888
   PubMed Web of Science ®Google Scholar
• Hohmann N, Kocheise F, Carls A, et al. Dose-dependent bioavailability and CYP3A inhibition contribute to non-linear pharmacokinetics of voriconazole. Clin Pharmacokinet. 2016;55(12):1535–1545. doi: 10.1007/s40262-016-0416-1
   PubMed Web of Science ®Google Scholar
• Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob Agents Chemother. 2009;53(2):541–551. doi: 10.1128/AAC.01123-08
   PubMed Web of Science ®Google Scholar
• Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 2006;79(4):362–370. doi: 10.1016/j.clpt.2005.12.305
   PubMed Web of Science ®Google Scholar
• Tintillier M, Kirch L, Goffin E, et al. Interaction between voriconazole and tacrolimus in a kidney-transplanted patient. Nephrol Dial Transplant. 2005;20(3):664–665. doi: 10.1093/ndt/gfh593
   PubMed Web of Science ®Google Scholar
• Capone D, Tarantino G, Gentile A, et al. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther. 2010;35(1):121–124. doi: 10.1111/j.1365-2710.2009.01070.x
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Pfizer Inc. VFEND® (voriconazole) prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208562s006lbl.pdf
   Google Scholar
• Mori T, Kato J, Yamane A, et al. Drug interaction between voriconazole and tacrolimus and its association with the bioavailability of oral voriconazole in recipients of allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2012;95(5):564–569. doi: 10.1007/s12185-012-1057-2
   PubMed Web of Science ®Google Scholar
• Vanhove T, Bouwsma H, Hilbrands L, et al. Determinants of the magnitude of interaction between tacrolimus and voriconazole/posaconazole in solid organ recipients. Am J Transplant. 2017;17(9):2372–2380. doi: 10.1111/ajt.14232
   PubMed Web of Science ®Google Scholar
• Outeda Macias M, Salvador Garrido P, Elberdin Pazos L, et al. Management of everolimus and voriconazole interaction in lung transplant patients. Ther Drug Monit. 2016;38(3):305–312. doi: 10.1097/FTD.0000000000000294
   PubMed Web of Science ®Google Scholar
• Mathis AS, Shah NK, Friedman GS. Combined use of sirolimus and voriconazole in renal transplantation: a report of two cases. Transplant Proc. 2004;36(9):2708–2709. doi: 10.1016/j.transproceed.2004.09.043
   PubMed Web of Science ®Google Scholar
• Surowiec D, Depestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy. 2008;28(6):719–729. doi: 10.1592/phco.28.6.719
   PubMed Web of Science ®Google Scholar
• Townsend R, Dietz A, Hale C, et al. Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):44–53. doi: 10.1002/cpdd.285
   PubMed Web of Science ®Google Scholar
• Kieu V, Jhangiani K, Dadwal S, et al. Effect of isavuconazole on tacrolimus and sirolimus serum concentrations in allogeneic hematopoietic stem cell transplant patients: a drug-drug interaction study. Transpl Infect Dis. 2019;21(1):e13007. doi: 10.1111/tid.13007
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Pfizer Inc. CRESEMBA® (isavuconazonium sulfate) prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500orig1s000lbl.pdf
   Google Scholar
• Kufel WD, Armistead PM, Daniels LM, et al. Drug-drug interaction between isavuconazole and tacrolimus: is empiric dose adjustment necessary? J Pharm Pract. 2020;33(2):226–230. doi: 10.1177/0897190018790688
   PubMed Web of Science ®Google Scholar
• Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother. 2012;56(5):2371–2377. doi: 10.1128/AAC.05219-11
   PubMed Web of Science ®Google Scholar
• Hashemizadeh Z, Badiee P, Malekhoseini SA, et al. Observational study of associations between voriconazole therapeutic drug monitoring, toxicity, and outcome in liver transplant patients. Antimicrob Agents Chemother. 2017;61(12). doi: 10.1128/AAC.01211-17
   PubMed Web of Science ®Google Scholar
• Luong ML, Hosseini-Moghaddam SM, Singer LG, et al. Risk factors for Voriconazole Hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant. 2012;12(7):1929–1935. doi: 10.1111/j.1600-6143.2012.04042.x
   PubMed Web of Science ®Google Scholar
• Butler-Laporte G, Langevin MC, Lemieux C, et al. Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis. Clin Transplant. 2022;36(8):e14709. doi: 10.1111/ctr.14709
   PubMed Web of Science ®Google Scholar
• Crone CG, Wulff SM, Helweg-Larsen J, et al. Adverse events associated with universal versus targeted antifungal prophylaxis among lung transplant recipients—A nationwide cohort study 2010–2019. Microorganisms. 2022;10(12):2478. doi: 10.3390/microorganisms10122478
   PubMed Web of Science ®Google Scholar
• Luong ML, Al-Dabbagh M, Groll AH, et al. Utility of voriconazole therapeutic drug monitoring: a meta-analysis. J Antimicrob Chemother. 2016;71(7):1786–1799. doi: 10.1093/jac/dkw099
   PubMed Web of Science ®Google Scholar
• Zhao YC, Lin XB, Zhang BK, et al. Predictors of adverse events and determinants of the voriconazole trough concentration in kidney transplantation recipients. Clin Transl Sci. 2021;14(2):702–711. doi: 10.1111/cts.12932
   PubMed Web of Science ®Google Scholar
• Ilyas M, Colegio OR, Kaplan B, et al. Cutaneous toxicities from transplantation-related medications. Am J Transplant. 2017;17(11):2782–2789. doi: 10.1111/ajt.14337
   PubMed Web of Science ®Google Scholar
• D’Arcy ME, Pfeiffer RM, Rivera DR, et al. Voriconazole and the risk of keratinocyte carcinomas among lung transplant recipients in the United States. JAMA Dermatol. 2020;156(7):772–779. doi: 10.1001/jamadermatol.2020.1141
   PubMed Web of Science ®Google Scholar
• Hamandi B, Fegbeutel C, Silveira FP, et al. Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study. Am J Transplant. 2018;18(1):113–124. doi: 10.1111/ajt.14500
   PubMed Web of Science ®Google Scholar
• Kolaitis NA, Duffy E, Zhang A, et al. Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation. Transplant Int. 2017;30(1):41–48. doi: 10.1111/tri.12865
   PubMed Web of Science ®Google Scholar
• Epaulard O, Villier C, Ravaud P, et al. A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: results from a French nationwide study. Clin Infect Dis. 2013;57(12):e182–188. doi: 10.1093/cid/cit600
   PubMed Web of Science ®Google Scholar
• Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis. 2011;52(5):604–611. doi: 10.1093/cid/ciq188
   PubMed Web of Science ®Google Scholar
• Wang TF, Wang T, Altman R, et al. Periostitis secondary to prolonged voriconazole therapy in lung transplant recipients. Am J Transplant. 2009;9(12):2845–2850. doi: 10.1111/j.1600-6143.2009.02837.x
   PubMed Web of Science ®Google Scholar
• Ayub A, Kenney CV, McKiernan FE. Multifocal nodular periostitis associated with prolonged voriconazole therapy in a lung transplant recipient. J Clin Rheumatol. 2011;17(2):73–75. doi: 10.1097/RHU.0b013e31820aff12
   PubMed Web of Science ®Google Scholar
• Wise SM, Wilson MA. A case of periostitis secondary to voriconazole therapy in a heart transplant recipient. Clin Nucl Med. 2011;36(3):242–244. doi: 10.1097/RLU.0b013e31820902d8
   PubMed Web of Science ®Google Scholar
• Sircar M, Kotton C, Wojciechowski D, et al. Voriconazole-induced periostitis & enthesopathy in solid organ transplant patients: case reports. J Biosci Med (Irvine). 2016;4(11):8–17. doi: 10.4236/jbm.2016.411002
   PubMedGoogle Scholar
• Bennett MJ, Balcerek MI, Lewis EA, et al. Voriconazole-Associated Periostitis: new insights into pathophysiology and management. JBMR Plus. 2022;6(2):e10557. doi: 10.1002/jbm4.10557
   PubMedGoogle Scholar
• Li H, Zhang M, Jiao X, et al. Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA adverse event reporting system database. Sci Rep. 2023;13(1):4475. doi: 10.1038/s41598-023-27687-0
   PubMed Web of Science ®Google Scholar
• Orssaud C, Guillemain R, Lillo Le Louet A. Toxic optic neuropathy due to voriconazole: possible potentiation by reduction of CYP2C19 activity. Eur Rev Med Pharmacol Sci. 2021;25(24):7823–7828. doi: 10.26355/eurrev_202112_27628
   PubMed Web of Science ®Google Scholar
• Assaf A, Faure E, Sermet K, et al. Successful treatment of Aspergillus fumigatus sternal osteomyelitis with isavuconazole in a heart transplant recipient. Transpl Infect Dis. 2020;22(5):e13313. doi: 10.1111/tid.13313
   PubMed Web of Science ®Google Scholar
• Soliman M, Akanbi O, Harding C, et al. Voriconazole-induced myositis in a double lung transplant recipient. Cureus. 2019;11(2):e3998. doi: 10.7759/cureus.3998
   PubMed Web of Science ®Google Scholar
• Trang TP, Hanretty AM, Langelier C, et al. Use of isavuconazole in a patient with voriconazole-induced QTc prolongation. Transpl Infect Dis. 2017;19(4). doi: 10.1111/tid.12712
   PubMed Web of Science ®Google Scholar
• Batista MV, Ussetti MP, Jiang Y, et al. Comparing the real-world use of isavuconazole to other anti-fungal therapy for invasive fungal infections in patients with and without underlying disparities: a multi-center retrospective study. J Fungi. 2023;9(2):166. doi: 10.3390/jof9020166
   Web of Science ®Google Scholar
• Ordaya EE, Alangaden GJ. Real-life use of Isavuconazole in patients intolerant to other azoles. Clin Infect Dis. 2016;63(11):1529–1530. doi: 10.1093/cid/ciw585
   PubMed Web of Science ®Google Scholar
• Hassouna H, Athans V, Brizendine KD. Real-world use-Isavuconazole at a large academic medical center. Mycoses. 2019;62(6):534–541. doi: 10.1111/myc.12910
   PubMed Web of Science ®Google Scholar
• Kato H, Hagihara M, Asai N, et al. A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections. Mycoses. 2023;66(9):815–824. doi: 10.1111/myc.13622
   PubMed Web of Science ®Google Scholar
• DiPippo AJ, Kontoyiannis DP. Lack of toxicity with Long-term isavuconazole use in patients with hematologic malignancy. Clin Infect Dis. 2019;69(9):1624–1627. doi: 10.1093/cid/ciz159
   PubMed Web of Science ®Google Scholar
• Lauruschkat CD, Einsele H, Loeffler J. Immunomodulation as a therapy for aspergillus infection: current status and future perspectives. J Fungi. 2018;4(4):137. doi: 10.3390/jof4040137
   Web of Science ®Google Scholar
• German CA, Liao JK. Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol. 2023;97(6):1529–1545. doi: 10.1007/s00204-023-03492-6
   PubMed Web of Science ®Google Scholar
• Tavakkoli A, Johnston TP, Sahebkar A. Antifungal effects of statins. Pharmacol Ther. 2020;208:107483. doi: 10.1016/j.pharmthera.2020.107483
   PubMed Web of Science ®Google Scholar
• Villalobos AP, Foroutan F, Davoudi S, et al. Statin use may be associated with a lower risk of invasive aspergillosis in lung transplant recipients. Clin Infect Dis. 2023;76(3):e1379–e1384. doi: 10.1093/cid/ciac551
   PubMed Web of Science ®Google Scholar
• Majima H, Arai T, Kamei K, et al. In vivo efficacy of pitavastatin combined with itraconazole against Aspergillus fumigatus in silkworm models. Microbiol Spectr. 2023;11(5):e0266623. doi: 10.1128/spectrum.02666-23
   PubMed Web of Science ®Google Scholar
• Lauruschkat C, Einsele H, Loeffler J. Immunomodulation as a therapy for Aspergillus infection: Current status and future perspectives. J Fungi. 2018;4(4):137. doi: 10.3390/jof4040137
   Web of Science ®Google Scholar
• Armstrong-James D, Teo IA, Shrivastava S, et al. Exogenous interferon-gamma immunotherapy for invasive fungal infections in kidney transplant patients. Am J Transplant. 2010;10(8):1796–1803. doi: 10.1111/j.1600-6143.2010.03094.x
   PubMed Web of Science ®Google Scholar
• Estrada C, Desai AG, Chirch LM, et al. Invasive aspergillosis in a renal transplant recipient successfully treated with interferon-gamma. Case Rep Transplant. 2012;2012:493758. doi: 10.1155/2012/493758
   PubMedGoogle Scholar
• Summers SA, Dorling A, Boyle JJ, et al. Cure of disseminated cryptococcal infection in a renal allograft recipient after addition of gamma-interferon to anti-fungal therapy. Am J Transplant. 2005;5(8):2067–2069. doi: 10.1111/j.1600-6143.2005.00947.x
   PubMed Web of Science ®Google Scholar
• Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584–591. doi: 10.1097/00007691-199512000-00007
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Singh N, Miller JL, et al. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus Isolates from transplant and nontransplant patients. Antimicrob Agents Chemother. 2004;48(12):4922–4925. doi: 10.1128/AAC.48.12.4922-4925.2004
   PubMed Web of Science ®Google Scholar
• Juvvadi PR, Lee SC, Heitman J, et al. Calcineurin in fungal virulence and drug resistance: Prospects for harnessing targeted inhibition of calcineurin for an antifungal therapeutic approach. Virulence. 2017;8(2):186–197. doi: 10.1080/21505594.2016.1201250
   PubMed Web of Science ®Google Scholar
• Gao L, Sun Y. In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms. Antimicrob Agents Chemother. 2015;59(11):7097–7099. doi: 10.1128/AAC.01510-15
   PubMed Web of Science ®Google Scholar
• Schwarz P, Dannaoui E. In vitro interaction between Isavuconazole and tacrolimus, cyclosporin a, or sirolimus against aspergillus species. J Fungi. 2020;6(3):103. doi: 10.3390/jof6030103
   Web of Science ®Google Scholar
• Sun S, Li Y, Guo Q, et al. In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother. 2008;52(2):409–417. doi: 10.1128/AAC.01070-07
   PubMed Web of Science ®Google Scholar
• Rossato L, Venturini TP, de Azevedo MI, et al. In vitro activity of immunosuppressive agents against Cryptococcus neoformans. Enferm Infecc Microbiol Clin (Engl Ed). 2022;40(2):86–88. doi: 10.1016/j.eimc.2020.09.014
   PubMedGoogle Scholar
• Steinbach WJ, Schell WA, Blankenship JR, et al. In vitro interactions between antifungals and immunosuppressants against aspergillus fumigatus. Antimicrob Agents Chemother. 2004;48(5):1664–1669. doi: 10.1128/AAC.48.5.1664-1669.2004
   PubMed Web of Science ®Google Scholar
• Singh N, Avery RK, Munoz P, et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis. 2003;36(1):46–52. doi: 10.1086/345441
   PubMed Web of Science ®Google Scholar
• Terrec F, Jouve T, Malvezzi P, et al. Belatacept use after kidney transplantation and its effects on risk of infection and COVID-19 vaccine response. J Clin Med. 2021;10(21):5159. doi: 10.3390/jcm10215159
   PubMed Web of Science ®Google Scholar
• McGaha T, Murphy JW, Mansfield JM. CTLA-4 down-regulates the protective anticryptococcal cell-mediated immune response. Infect Immun. 2000;68(8):4624–4630. doi: 10.1128/IAI.68.8.4624-4630.2000
   PubMed Web of Science ®Google Scholar
• Roussey JA, Viglianti SP, Teitz-Tennenbaum S, et al. Anti-PD-1 antibody treatment promotes clearance of persistent cryptococcal lung infection in mice. J Immunol. 2017;199(10):3535–3546. doi: 10.4049/jimmunol.1700840
   PubMed Web of Science ®Google Scholar
• Wurster S, Watowich SS, Kontoyiannis DP. Checkpoint inhibitors as immunotherapy for fungal infections: promises, challenges, and unanswered questions. Front Immunol. 2022;13:1018202.
   PubMedGoogle Scholar
• Vu CTB, Thammahong A, Yagita H, et al. Blockade of PD-1 attenuated postsepsis aspergillosis via the activation of IFN-gamma and the dampening of IL-10. Shock. 2020;53(4):514–524. doi: 10.1097/SHK.0000000000001392
   PubMed Web of Science ®Google Scholar
• Wurster S, Robinson P, Albert ND, et al. Protective activity of programmed cell death protein 1 blockade and synergy with caspofungin in a murine invasive pulmonary aspergillosis model. J Infect Dis. 2020;222(6):989–994. doi: 10.1093/infdis/jiaa264
   PubMed Web of Science ®Google Scholar
• Wurster S, Albert ND, Bharadwaj U, et al. Blockade of the PD-1/PD-L1 immune checkpoint pathway improves infection outcomes and enhances fungicidal host defense in a murine model of invasive pulmonary mucormycosis. Front Immunol. 2022;13:838344. doi: 10.3389/fimmu.2022.838344
   PubMed Web of Science ®Google Scholar
• Grimaldi D, Pradier O, Hotchkiss RS, et al. Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17(1):18. doi: 10.1016/S1473-3099(16)30541-2
   PubMed Web of Science ®Google Scholar
• Banck JC, Mueller N, Mellinghoff SC, et al. Immune checkpoint blockade for aspergillosis and Mucormycosis Coinfection. Hemasphere. 2021;5(3):e530. doi: 10.1097/HS9.0000000000000530
   PubMed Web of Science ®Google Scholar
• Khatamzas E, Mellinghoff SC, Thelen M, et al. Nivolumab induces long-term remission in a patient with fusariosis. Eur J Cancer. 2022;173:91–94. doi: 10.1016/j.ejca.2022.06.035
   PubMed Web of Science ®Google Scholar
• Serris A, Ouedrani A, Uhel F, et al. Case report: immune checkpoint blockade plus interferon-gamma add-on antifungal therapy in the treatment of refractory Covid-associated pulmonary aspergillosis and cerebral mucormycosis. Front Immunol. 2022;13:900522. doi: 10.3389/fimmu.2022.900522
   PubMed Web of Science ®Google Scholar
• Lukaszewicz AC, Venet F, Boibieux A, et al. Nivolumab and interferon-gamma rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock. Med Mycol Case Rep. 2022;37:19–22. doi: 10.1016/j.mmcr.2022.06.003
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu G, Li L, et al. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: a systematic review of the literature. Transplant Rev (Orlando). 2022;36(4):100712. doi: 10.1016/j.trre.2022.100712
   PubMedGoogle Scholar
• Tio M, Rai R, Ezeoke OM, et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection. Eur J Cancer. 2018;104:137–144. doi: 10.1016/j.ejca.2018.09.017
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7(1):106. doi: 10.1186/s40425-019-0585-1
   PubMed Web of Science ®Google Scholar
• Benedict K, Gold JAW, Toda M, et al. Low rates of antifungal therapeutic drug monitoring among inpatients who received itraconazole, posaconazole, or voriconazole, United States, 2019-2021. Open Forum Infect Dis. 2023;10(8):ofad389. doi: 10.1093/ofid/ofad389
   PubMed Web of Science ®Google Scholar
• Höhl R, Bertram R, Kinzig M, et al. Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis. Mycoses. 2022;65(7):747–752. doi: 10.1111/myc.13469
   PubMed Web of Science ®Google Scholar
• De Francesco MA. Drug-resistant aspergillus spp: a literature review of its resistance mechanisms and its prevalence in Europe. Pathogens. 2023;12(11):1305. doi: 10.3390/pathogens12111305
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Carvalhaes CG, Rhomberg PR, et al. Trends in the activity of mold-active azole agents against aspergillus fumigatus clinical isolates with and without cyp51 alterations from Europe and North America (2017–2021). J Clin Microbiol. 2024 Jan;9(2):e0114123. epub ahead of print. doi: 10.1128/jcm.01141-23
   Google Scholar
• Gioia F, Filigheddu E, Corbella L, et al. Invasive aspergillosis in solid organ transplantation: diagnostic challenges and differences in outcome in a Spanish national cohort (diaspersot study). Mycoses. 2021;64(11):1334–1345. doi: 10.1111/myc.13298
   PubMed Web of Science ®Google Scholar
• Redondo N, Navarro D, Aguado JM, et al. Viruses, friends, and foes: the case of torque teno virus and the net state of immunosuppression. Transpl Infect Dis. 2022;24(2):e13778. doi: 10.1111/tid.13778
   PubMed Web of Science ®Google Scholar
• Lamoth F, Lewis RE, Kontoyiannis DP. Investigational antifungal agents for invasive mycoses: a clinical perspective. Clin Infect Dis. 2022;75(3):534–544. doi: 10.1093/cid/ciab1070
   PubMed Web of Science ®Google Scholar
• Gintjee TJ, Donnelley MA, Thompson GR. 3rd. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi. 2020;6(1):28. doi: 10.3390/jof6010028
   Web of Science ®Google Scholar
• Faure E, Brugiere O, de Verdiere SC, et al. Refractory microascus bronchopulmonary infection treated with olorofim, France. Emerg Infect Dis. 2023;29(11):2401–2403. doi: 10.3201/eid2911.230984
   PubMed Web of Science ®Google Scholar